GP2 Inhibitors
The chemical class known as GP2 inhibitors represents a diverse group of compounds specifically designed to target and inhibit the activity of the GP2 protein. GP2, also known as glycoprotein 2, is a cell surface receptor primarily expressed in the gastrointestinal tract, where it plays a crucial role in immune response and antigen presentation. GP2 is involved in various cellular processes, including endocytosis and immune surveillance. Researchers have identified several small molecules that exhibit inhibitory effects on GP2 function. These inhibitors are characterized by their ability to interfere with the molecular interactions involving GP2, disrupting its normal cellular processes.
Structurally, GP2 inhibitors encompass a wide range of chemical entities, including peptides, small organic molecules, and peptidomimetics. These compounds often bind to specific regions of the GP2 protein, disrupting its binding capabilities with ligands or interfering with its downstream signaling pathways. The design and development of GP2 inhibitors involve extensive structural and computational studies to identify key binding sites and optimize the inhibitory properties of the compounds. Researchers employ techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling to understand the molecular interactions between GP2 and its inhibitors.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LCL-161 | 1005342-46-0 | sc-507541 | 10 mg | $360.00 | ||
LCL161 is a small molecule inhibitor of apoptosis proteins (IAP) antagonist. It suppresses GP2 by binding to IAPs, promoting their degradation and allowing apoptosis to proceed. | ||||||
Q-VD-OPH | 1135695-98-5 | sc-222230 | 5 mg | $782.00 | 5 | |
Q-VD-OPh is a broad-spectrum caspase inhibitor. It inhibits GP2 by targeting and inhibiting multiple caspases, preventing their activation and subsequent apoptotic processes. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor. It inhibits GP2 by binding irreversibly to the active site of caspases, preventing their proteolytic activity and inhibiting the apoptotic pathway. | ||||||
Emricasan | 254750-02-2 | sc-507387 | 5 mg | $90.00 | ||
Emricasan is a pan-caspase inhibitor. It inhibits GP2 by interfering with caspase activation, preventing apoptotic cell death and promoting cell survival in various pathological conditions. | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | $132.00 $536.00 | 1 | |
PAC 1 is a procaspase-3 activator. It inhibits GP2 by directly activating procaspase-3, leading to the initiation of the apoptotic cascade and inducing cell death in cancer cells. | ||||||
WEHI-539 | 1431866-33-9 | sc-507317 | 5 mg | $233.00 | ||
WEHI-539 is a selective BCL-XL inhibitor. It inhibits GP2 by binding to BCL-XL, preventing its interaction with pro-apoptotic proteins and promoting mitochondrial-mediated apoptosis in cells. | ||||||
ABT 263 | 923564-51-6 | sc-207241 | 5 mg | $245.00 | 16 | |
ABT-263 is a BCL-2, BCL-XL, and BCL-W inhibitor. It inhibits GP2 by targeting these anti-apoptotic proteins, releasing pro-apoptotic proteins like Bak and Bax, initiating apoptosis in cells. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 is a BCL-2 inhibitor. It inhibits GP2 by specifically targeting BCL-2, disrupting its interaction with pro-apoptotic proteins, leading to mitochondrial outer membrane permeabilization and apoptosis. | ||||||